Tricetin |
| Catalog No.GC64862 |
Tricétine est un inhibiteur compétitif puissant de l'interaction protéine-protéine (PPI) Keap1-Nrf2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 520-31-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tricetin is a potent competitive inhibitor of the Keap1-Nrf2 Protein Protein Interaction (PPI). Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson's disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway[1].
Tricetin is mainly found in natural plants such as Ginkgo biloba L., Carica papaya L. and Murraya exotica L. Tricetin activates the Nrf2/HO-1 pathway to protect cells from oxidative stress. Tricetin possessed the protective effect on dopamine neurons of C. elegans. Tricetin has cytostatic properties and anti-metastatic activity of various solid tumors[1].Pretreatment with Tricetin (20, 40, and 80 μM; for 4 hours) significantly improves 6-OHDA (200 μM)-induced SH-SY5Y cells viability and suppresses mitochondria-mediated apoptosis[1].Tricetin (80 μM; for 1, 2 and 4 h) markedly decreased the expressions of p-JNK and p-p38[1].
[1]. Ren J, et al. Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson's disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway. Toxicol Appl Pharmacol. 2019;378:114617.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *